Physician profile
Jaime Goebel
NPI 1871261040
$2,668.80
in general payments reported to CMS, 2019-2025
23 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $790 · 2023: $793 · 2024: $766 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.16 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $368.92 | 2022-2024 | |
| Janssen Biotech, INC. | $270.80 | 2022-2024 | Erleada, Tecvayli, Carvykti |
| Genzyme Corporation | $242.14 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $240.67 | 2021-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $174.14 | 2022-2025 | Keytruda |
| Exelixis INC. | $154.02 | 2022-2025 | Cabometyx |
| Abbvie INC. | $125.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.09 | 2023 | |
| Acrotech Biopharma INC. | $120.35 | 2022 | |
| Aveo Pharmaceuticals, INC. | $119.00 | 2024-2025 | |
| Seagen INC. | $112.20 | 2022-2023 | Padcev |
| Emd Serono, INC. | $108.33 | 2024 | |
| Adc Therapeutics America, INC. | $100.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $74.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $64.83 | 2023-2024 | Libtayo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $64.00 | 2023 | Xpovio |
| Novartis Pharmaceuticals Corporation | $43.10 | 2023-2024 | |
| Astellas Pharma US INC | $43.07 | 2023 | Xtandi |
| Janssen Scientific Affairs, LLC | $34.84 | 2023 | Erleada, Abiraterone Acetate, Balversa |
| Dendreon Pharmaceuticals LLC | $32.53 | 2024 | Provenge |
| Amgen INC. | $18.87 | 2022 | |
| Progenics Pharmaceuticals, INC. | $18.33 | 2023 | Pylarify |
| Boston Scientific Corporation | $16.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Goebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.